U.S. companies, labs rush to produce blood test for coronavirus immunity

  • 📰 YahooNews
  • ⏱ Reading Time:
  • 108 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 46%
  • Publisher: 59%

Nigeria News News

Nigeria Nigeria Latest News,Nigeria Nigeria Headlines

Several academic laboratories and medical companies are rushing to produce these blood tests, which can quickly identify disease-fighting antibodies in people who already have been infected but may have had mild symptoms or none at all. This is different from the current, sometimes hard-to-come-by diagnostic

1 / 2FILE PHOTO: Specimens from coronavirus disease tests are logged to processed for a positive or negative result at the UW Medicine Virology lab in Seattle,By Chad Terhune, Allison Martell and Julie Steenhuysen

Several private companies have begun selling blood tests for COVID-19 antibodies outside the United States, including California-based Biomerica Inc and South Korean test maker Sugentech Inc . Biomerica said its test sells for less than $10 and the company already has orders from Europe and the Middle East. Chembio Diagnostics Inc of New York said it received a $4 million order from Brazil for its COVID-19 antibody test, and it plans a study of the test at several sites in the United States.

Detecting immunity among doctors, nurses and other healthcare workers could spare them from quarantine and enable them to keep treating the growing surge of coronavirus patients, they say. It could also bolster the ranks of first responders, police officers and other essential workers who have already been infected and have at least some period of protection from the virus, the experts say.

Tony Mazzulli, chief microbiologist with Toronto's Sinai Health system, sounded a note of caution. It is uncertain whether antibodies would be sufficient protection if a person were to be re-exposed to the virus in very large amounts. That could happen in an emergency room or intensive-care unit, for instance.

The trial is designed to show when people who have COVID-19 infections “seroconvert” - when antibodies produced by the body begin to show up in blood tests. That information will be useful in determining the best time to conduct the tests. The agency faced heavy criticism for sending a faulty diagnostic test to state and local labs early in the coronavirus epidemic and then taking weeks to fix it. The federal government is still trying to expand diagnostic testing capacity.The potential for antibody testing arises as U.S. President Donald Trump is considering scaling back “social distancing” and stay-at-home advisories in the weeks ahead. His political allies argue that the toll on the U.S. economy is too severe.

“Some are developed now. We are looking at the ones in Singapore,” Birx said Monday at a White House press briefing. “We are very quality-oriented. We don’t want false positives.”

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 380. in NG

Nigeria Nigeria Latest News, Nigeria Nigeria Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

U.S. companies, labs rush to produce blood test for coronavirus immunityAs the United States works overtime to screen thousands for the novel coronaviru... 'proceed to market without full agency review and approval'—Sounds like Trump's idea of a work-screening test, complete with plenty of false positives for the antibodies and more divisive elements for political advantage: 'Trump's immunity test got me my job back!' blare the ads. LATIN CURSE' WILL FALL ON TRUMP AND THE 'REPUBLICANS' FOR ILL-TREATMENT OF CHILDREN, YOUNG PEOPLE, AND ADULTS, 'LATIN IMMIGRANTS' FOR 'THEFT', 'SANCTIONS', 'BLOCKAGES', TO CUBA AND VENEZUELA, EVIDENTLY WIN OF SANDMARK , RETWITEAR Return to work where.. when EarthIsOnLockdown
Source: Reuters - 🏆 2. / 97 Read more »